A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under ...
Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.
Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.
Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...
Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...
The number of U.S. women with breast cancer that has spread elsewhere in the body by the time of diagnosis increased ...
Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...
About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months ...
This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...